Ilyang Pharmaceutical

At a glance

Ilyang Pharmaceutical filed 52 disclosures in the last 12 months, including 8 insider, 3 5% holder and 1 contract. The most recent key filing was on Sep 23.

Revenue for 2025 was ₩272B, up 1.4% on 2024. Operating margin was 1.8% against 3.6% a year earlier. Debt was 89% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩130B and operating loss of ₩14.1B.

The 2025 annual report lists 665 employees with an average tenure of 9.7 years and average pay of ₩84.3M, #302 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩108M each on average. It paid ₩155 per common share in cash dividends, against ₩150 a year earlier (+3.3%). 정도언 and related parties held 26.84% at year end.

From the 2025 annual report

Staff: 665 (528 men, 137 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩56.3B. Directors and auditors: 8, paid ₩866M in total.

Dividends (common shares)

Largest shareholder

정도언 holds 21.84%; with 7 related parties the group holds 26.84% of common shares at year end (from 26.79% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary